Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Original Investigation titled “Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer,”1 published online July 8, 2021, there was an error in the Results section of the Abstract. The median (interquartile range) overall survival and time on treatment was 43 (16.2-unavailable) and 14 (6.0-26.22) months, respectively, among the cohort of patients who received pertuzumab, rather than the entire population. This article has been corrected online.
Error in Abstract. JAMA Oncol. 2021;7(9):1406. doi:10.1001/jamaoncol.2021.4035
Oncology in JAMA: Read the Latest